Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 517

1.

Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.

Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, Akahane D, Okabe S, Tauchi T, Ito Y, Ohyashiki K.

Transpl Infect Dis. 2014 Jun;16(3):440-9. doi: 10.1111/tid.12229. Epub 2014 May 9.

PMID:
24810656
[PubMed - in process]
2.

[Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia].

Katagiri S, Yoshizawa S, Gotoh M, Nakamura I, Ohyashiki K.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):734-7. Japanese. No abstract available.

PMID:
24796145
[PubMed - indexed for MEDLINE]
3.

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.

J Hematol Oncol. 2014 Apr 28;7(1):37. doi: 10.1186/1756-8722-7-37.

PMID:
24775308
[PubMed - in process]
Free PMC Article
4.

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, Akahane D, Okabe S, Tauchi T, Ito Y, Ohyashiki K.

Bone Marrow Transplant. 2014 Jul;49(7):955-60. doi: 10.1038/bmt.2014.66. Epub 2014 Apr 14.

PMID:
24732960
[PubMed - in process]
5.

Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH.

Biochem Pharmacol. 2014 Jun 1;89(3):361-9. doi: 10.1016/j.bcp.2014.03.008. Epub 2014 Mar 26.

PMID:
24680865
[PubMed - indexed for MEDLINE]
6.

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y, Ohyashiki K.

PLoS One. 2014 Feb 28;9(2):e89080. doi: 10.1371/journal.pone.0089080. eCollection 2014.

PMID:
24586514
[PubMed - in process]
Free PMC Article
7.

Genetic variants in C5 and poor response to eculizumab.

Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y.

N Engl J Med. 2014 Feb 13;370(7):632-9. doi: 10.1056/NEJMoa1311084.

PMID:
24521109
[PubMed - indexed for MEDLINE]
8.

Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, Katoh T, Kusumoto M, Gemma A, Sakai F, Sugiyama Y, Hatake K, Fukuda Y, Kudoh S.

Cancer Sci. 2014 Feb;105(2):195-201. doi: 10.1111/cas.12335. Epub 2014 Jan 21.

PMID:
24329927
[PubMed - indexed for MEDLINE]
9.

Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.

Okabe S, Tauchi T, Tanaka Y, Katagiri S, Kitahara T, Ohyashiki K.

Blood. 2013 Oct 24;122(17):3086-8. doi: 10.1182/blood-2013-04-494773. No abstract available.

PMID:
24159169
[PubMed - indexed for MEDLINE]
10.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.

PMID:
24133215
[PubMed - indexed for MEDLINE]
11.

Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes.

Kimura Y, Gotoh A, Katagiri S, Hoshi Y, Uchida S, Yamasaki A, Takahashi Y, Fukutake K, Kiguchi T, Ohyashiki K.

Blood Transfus. 2014 Jan;12(1):103-6. doi: 10.2450/2013.0081-13. Epub 2013 Oct 2. No abstract available.

PMID:
24120594
[PubMed - in process]
Free PMC Article
12.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725. Epub 2013 Nov 8.

PMID:
24100660
[PubMed - in process]
13.

Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.

Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Ozawa K, Omine M.

Int J Hematol. 2013 Oct;98(4):406-16. doi: 10.1007/s12185-013-1404-y. Epub 2013 Aug 11.

PMID:
23934275
[PubMed - in process]
14.

Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.

Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T.

J Infect Chemother. 2013 Dec;19(6):1126-34. doi: 10.1007/s10156-013-0634-5. Epub 2013 Jun 28.

PMID:
23813092
[PubMed - in process]
Free PMC Article
15.

Monosomal karyotype in MDS: explaining the poor prognosis?

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21.

PMID:
23787396
[PubMed - indexed for MEDLINE]
16.

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K.

Cancer Sci. 2013 Sep;104(9):1146-53. doi: 10.1111/cas.12216. Epub 2013 Jul 9.

PMID:
23758044
[PubMed - indexed for MEDLINE]
17.

Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.

Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.

Biochem Biophys Res Commun. 2013 Jun 7;435(3):506-11. doi: 10.1016/j.bbrc.2013.05.022. Epub 2013 May 14.

PMID:
23684619
[PubMed - indexed for MEDLINE]
18.

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.

Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K.

Cancer Cell Int. 2013 Apr 4;13(1):32. doi: 10.1186/1475-2867-13-32.

PMID:
23556431
[PubMed]
Free PMC Article
19.

[Successful treatment with rituximab for autoimmune hemolytic anemia associated with chronic lymphocytic leukemia].

Tanaka Y, Ito Y, Yoshizawa S, Fujimoto H, Gotoh M, Tauchi T, Kimura Y, Ohyashiki K.

Rinsho Ketsueki. 2013 Feb;54(2):229-31. Japanese.

PMID:
23470833
[PubMed - indexed for MEDLINE]
20.

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease.

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K.

Int J Mol Med. 2013 Mar;31(3):533-9. doi: 10.3892/ijmm.2013.1251. Epub 2013 Jan 21.

PMID:
23338559
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk